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We performed a clinical study to identify biological markers useful for the treatment of resectable non-small-cell lung cancers
(NSCLCs). In all, 173 patients were studied. By immunohistochemistry, we evaluated the Ki-67 proliferation index, tumour vascularity,
thymidylate synthase (TS), vascular endothelial growth factor (VEGF)-A, VEGF-C, and E (epithelial)-cadherin. Concerning the survival
of NSCLC patients, tumour vascularity (Po0.01), VEGF-A status (P¼0.03), VEGF-C status (P¼0.03), and E-cadherin status
(P¼0.03) were significant prognostic factors in patients with stage I NSCLCs. The Ki-67 proliferation index (P¼0.02) and TS status
(Po0.01) were significant prognostic factors in patients with stage II–III NSCLCs. In patients with stage II–III NSCLCs, furthermore,
the survival of UFT (a combination of tegafur and uracil)-treated patients with TS-negative tumours was significantly better than those
of any other patients. Biological markers associated with tumour angiogenesis or metastasis are useful for the detection of aggressive
tumours among early-stage NSCLCs. Postoperative chemotherapy might be necessary in such tumours even in stage I. In contrast,
tumour proliferation rate and TS status are useful markers for identifying less aggressive tumours in locally advanced NSCLCs.
Thymidylate synthase expression is also a useful marker to evaluate responsiveness of UFT-based chemotherapy for these tumours.
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Non-small-cell lung cancer (NSCLC) is one of the most common
human malignancies with a poor prognosis. Surgical resections
play major roles in managing patients with stage I and stage II
NSCLCs, and may be used for patients with stage III NSCLCs
(Cersosimo, 2002). In addition, various combined-modality
therapy, including chemotherapy and radiation therapy, have
been assessed for improving the outcome of patients with NSCLCs
(Arriagada et al, 2004; Machtay et al, 2004; Strauss et al, 2004;
Winton et al, 2004). However, the 3-year survival of stage II
NSCLC patients was 35–55%, and the 3-year survival of resectable
stage III NSCLC patients was 28% (Martin et al, 2002). Therefore, a
new therapeutic strategy is required for patients with resectable
NSCLCs.
Owing to developments in molecular biology, many clinical
studies on molecular markers associated with tumour biological
behaviour have been performed in human cancers, and these
molecular markers, including oncogenes, tumour suppressor genes
(Huang et al, 1998), metastatic suppressor genes (Adachi et al,
1998; Sulzer et al, 1998), and angiogenetic factors (Imoto et al,
1998; Masuya et al, 2001), could be prognostic factors for NSCLC
patients. Therefore, to improve the treatment of NSCLC patients, it
is important to decide the optimal therapeutic strategy for them
according to the tumour biology. Our previous studies demon-
strated four biological markers, including thymidylate synthase
(TS) (Huang et al, 2000), vascular endothelial growth factor-A
(VEGF-A), VEGF-C (Nakashima et al, 2004), and E (epithelial)-
cadherin (Liu et al, 2001), to be significant prognostic factors for
NSCLC patients. Thymidylate synthase is reported to be related to
tumour cell proliferation and responsiveness to 5-FU-based
chemotherapy (Navalgund et al, 1980; Beck et al, 1994). VEGF-A
and VEGF-C are members of the VEGF family associated with
angiogenesis or lymphangiogenesis (Dvorak et al, 1995; Skobe
et al, 2001). E-cadherin is one of the metastatic suppressor genes
(Mbalaviele et al, 1996; Sulzer et al, 1998).
Therefore, we performed a retrospective clinical study to
identify molecular markers useful for the treatment of patients
with resectable NSCLCs. We evaluated the intratumoral expres-
sions of these four biological markers: TS, VEGF-A, VEGF-C, and
E-cadherin. In addition, we studied the tumour proliferation rate
using the Ki-67 index (Gerdes et al, 1984; Scagliotti et al, 1993) and
tumour angiogenesis using CD34 staining (Matsuyama et al, 1998).
MATERIALS AND METHODS
Clinical characteristics of patients
From January 1995 to December 1997, consecutive NSCLC patients
who underwent surgery at the Second Department of Surgery,
Faculty of Medicine, Kagawa University were studied. This study
was approved by the institutional review board of Kagawa
University (14-7, a clinical study of biological markers in NSCLCs).
TNM staging designations were made according to the postsurgical
pathological international staging system (Mountain, 1997). In
total, 173 patients with lung cancer up to stage III were
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sinvestigated (Table 1). These included 97 patients with stage I
NSCLCs, 17 patients with stage II NSCLCs, and 59 patients with
stage III NSCLCs. Patients’ clinical records and histopathological
diagnoses were fully documented. This report includes follow-up
data as of 31 March 2004. The median follow-up period for all
patients was 77.0728.9 months.
Regarding methods of surgical resection, a pneumonectomy was
performed in 16 patients with stage II–III NSCLCs. A lobectomy
was performed in 133 patients: 73 patients with stage I NSCLCs, 15
patients with stage II NSCLCs, and 45 patients with stage III
NSCLCs. A segmentectomy was performed in three patients with
stage I NSCLCs, and a wedge resection was performed in 21
patients with stage I NSCLCs. Systemic chemotherapy using
mitomycin/vinblastin/cisplatin (MVP) was performed in all
patients with stage II–III NSCLCs; neoadjuvant chemotherapy in
49 patients, and postoperative adjuvant chemotherapy in 27
patients with nodal metastases. Radiation therapy was performed
in 18 patients: 11 patients with T3 or T4 status and seven patients
with mediastinal lymph node metastases. 5-FU was administered
as UFT (a combination of tegafur and uracil, Taiho Pharmaceutical
Co., Tokyo, Japan; 300–400mgday
 1body
 1) to 107 patients
including 53 patients with stage I NSCLCs and 54 patients with
stage II–III NSCLCs. Oral administration of UFT was started
within 1 month after surgery. UFT was administered for 2 years if
there was no recurrence of carcinomas. In patients with
recurrences, UFT was given until its oral administration became
impossible.
Immunohistochemistry
The following antibodies were used, along with isotype antibodies
as negative controls: a mouse monoclonal antibody for the Ki-67
antigen (MIB-1, DAKO, Glostrup, Denmark) diluted at 1:40, a
mouse monoclonal antibody for CD34 (NU-4A1, Nichirei Corpora-
tion, Tokyo, Japan) diluted at 1:10, a rabbit polyclonal antibody
for TS (kindly provided by Dr M Fukushima) (Huang et al, 2000)
diluted at 1:500, a rabbit polyclonal antibody for VEGF-A (A-20,
Santa Cruz Biotechnology, Santa Cruz, CA, USA) diluted at 1:200,
a goat polyclonal antibody for VEGF-C (N-19, Santa Cruz
Biotechnology) diluted at 1:100, and a mouse monoclonal
antibody for E-cadherin (HECD-1, Takara, Otsu, Japan) diluted
at 1:400.
Formalin-fixed paraffin-embedded tissue was cut into 4-mm
sections and mounted onto poly-L-lysine-coated slides. Sections
were deparaffinised and rehydrated. The slides were then heated in
a microwave for 10min in a 10-mmoll
 1 citrate buffer solution at
pH 6.0, and cooled to room temperature for 20min. After
quenching the endogenous peroxidase activity with 0.3% H2O2
(in absolute methanol) for 30min, the sections were treated for 2h
at room temperature with 5% bovine serum albumin to block
nonspecific staining. Duplicate sections were incubated overnight
with the primary specific antibodies detecting Ki-67, CD34, TS,
VEGF-A, VEGF-C, and E-cadherin. Slides were then incubated for
1h with biotinylated anti-mouse IgG (Vector Laboratories Inc.,
Burlingame, CA, USA) for Ki-67, CD34, and E-cadherin, biotiny-
lated anti-rabbit IgG (Vector Laboratories Inc.) for TS and VEGF-
A, and biotinylated anti-goat IgG (Vector Laboratories Inc.) for
VEGF-C. The sections were incubated with the avidin–biotin–
peroxidase complex (Vector Laboratories Inc.) for 1h, and
antibody binding was visualised with 3,30-diaminobenzidine
tetrahydrochloride. Lastly, the sections were lightly counterstained
with Mayer’s haematoxylin. The human colon cancer cell line
DLD-1/FrUrd was used as a positive control for the staining of TS.
Sections of resected lung tumours known to express VEGF-A,
VEGF-C, or E-cadherin were used as positive controls for
immunohistochemic staining, respectively.
Assessment of immunohistochemical staining
All of the immunostained sections were reviewed by two
pathologists (M Ueno and R Haba) who had no knowledge of
the patients’ clinical status. The percentage of carcinoma cells with
positive staining for Ki-67 in a given specimen was scored as the
Ki-67 proliferation index, and tumours with X25% of Ki-67
proliferation index were classified as high Ki-67 (Scagliotti et al,
1993). For microvessel quantification, the three most highly
vascularised areas detected by CD34 immunostaining were initially
selected under the  40 field, and a  200 field (0.785mm
2 per
field) was used to count vessels in each of these areas. The average
of three  200 field counts was recorded as the intratumoral
microvessel density (IMD). Tumours with X90 of the IMD were
classified as hypervascular (Masuya et al, 2001).
For TS, VEGF-A VEGF-C, and E-cadherin, samples were
classified into two groups, positive or negative, with a cutoff value
based on the findings of previous reports, respectively. At least 200
tumour cells were scored per  40 field. All sections were scored in
a semiquantitative manner according to the method described
previously, which reflects both the intensity and percentage of cells
staining at each intensity (McCarty et al, 1986). Intensity was
Table 1 Patient demographics
Patient characteristics Number (%)
Total number of patients 173 100
Age (years)
Median 67
Range 35–76
Gender
Male 116 67
Female 57 33
Smoking habits
Nonsmoker 65 38
Smoker 108 62
ECOG performance status
08 3 4 8
17 4 4 3
21 6 9
Histology
Adenocarcinoma 101 58
Squamous cell carcinoma 58 34
Large-cell carcinoma 14 8
Pathological stage
I9 7 5 6
II 17 10
III 59 34
Method of surgical resection
Pneumonectomy 16 9
Lobectomy 133 77
Segmentectomy 3 2
Wedge resection 21 12
Chemotherapy
MVP 76 44
Neoadjuvant therapy 49 28
Postoperative adjuvant therapy 27 16
UFT 107 62
Radiotherapy 18 10
ECOG¼Eastern Cooperative Oncology Group; MVP¼mitomycin/vinblastin/cispla-
tin; UFT¼a combination of tegafur and uracil.
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sclassified as 0 (no staining), þ1 (weak staining), þ2 (distinct
staining), or þ3 (very strong staining). A value designated the
‘HSCORE’ was obtained for each slide by using the following
algorithm: HSCORE¼S(I PC), where I and PC represent
staining intensity and the percentage of cells that stain at each
intensity, respectively, and the corresponding HSCOREs were
calculated separately. Concerning TS expression, when the
HSCORE of TS in a given specimen was X30, the sample was
classified as TS-positive (Huang et al, 2000). Expressions of VEGF-
A, VEGF-C, and E-cadherin were classified as follows: when X30%
of the carcinoma cells in a given specimen were positively stained
for VEGF-A, the sample was classified as VEGF-A-positive
(Masuya et al, 2001); when X30% of the carcinoma cells in a
given specimen were positively stained for VEGF-C, the sample
was classified as VEGF-C-positive (Arinaga et al, 2003); and when
X50% of the carcinoma cells in a given specimen were positively
stained for E-cadherin, the sample was classified as E-cadherin-
positive (Liu et al, 2001).
Statistical analysis
The statistical differences in the expression of each biological
marker in relation to various clinical and pathological parameters
were assessed by the w
2 test. Overall survival was defined as the
time from treatment initiation (surgical resection, chemotherapy,
or radiation) to the date of death from any cause. The Kaplan–
Meier method was used to estimate the probability of overall
survival as a function of time, and differences in the survival of
subgroups of patients were compared by using Mantel’s log-rank
test. Multivariate analyses were performed using the Cox regres-
sion model to study the effects on survival (Cox, 1972). The
validity of the proportional hazards assumption was investigated
by graphical methods (Grambsch and Therneau, 1994). All P-
values were based on two-tailed statistical analysis, and a P-value
o0.05 was considered to indicate statistical significance.
RESULTS
Distribution of biological markers in NSCLCs
Concerning the Ki-67 proliferation index, 117 carcinomas (67.6%)
had high Ki-67 (Table 2). The frequency of high Ki-67 tumours was
significantly higher in squamous cell carcinomas than in
adenocarcinomas (87.9 vs 56.4%, Po0.01). However, there was
no difference in the Ki-67 index in relation to tumour status, nodal
status, pathological stage, or neoadjuvant chemotherapy.
With respect to tumour angiogenesis, 93 carcinomas (53.8%)
were hypervascular tumours. The frequency of hypervascular
tumours was significantly higher in adenocarcinomas than in
squamous cell carcinomas (65.3 vs 32.8%, Po0.01). There was no
difference in the IMD according to tumour status, nodal status,
pathological stage, or neoadjuvant chemotherapy.
Concerning the intratumoral TS expression status, 93 carcino-
mas (53.8%) were TS-positive. The frequency of TS-positive
tumours was significantly higher in squamous cell carcinomas
than in adenocarcinomas (72.4 vs 43.6%, Po0.01). There was also
no difference in TS status according to tumour status, nodal status,
pathological stage, or neoadjuvant chemotherapy.
In all, 91 carcinomas (52.6%) were VEGF-A-positive tumours.
There was no difference in VEGF-A status in relation to tumour
histology or neoadjuvant chemotherapy. However, the frequency
of nodal metastases was significantly higher in VEGF-A-positive
tumours than in VEGF-A-negative tumours (37.4 vs 23.2%,
P¼0.04).
A total of 73 carcinomas (42.2%) were VEGF-C-positive
tumours. There was no difference in VEGF-C status in relation
to tumour histology, tumour status, nodal status, pathological
stage, or neoadjuvant chemotherapy.
In total, 98 carcinomas (56.6%) were E-cadherin-negative. There
was no difference in E-cadherin status in relation to tumour
histology or neoadjuvant chemotherapy. However, the frequency
Table 2 Distribution of biological markers in 173 NSCLC patients according to clinicopathological characteristics
High Ki-67 Hypervascular TS-positive VEGF-A-positive VEGF-C-positive E-cadherin-negative
Characteristics n (%) P-value (%) P-value (%) P-value (%) P-value (%) P-value (%) P-value
Smoking
Nonsmoker 65 50.8 o0.01 61.5 0.15 53.8 0.98 49.2 0.49 38.5 0.44 55.4 0.79
Smoker 108 77.8 49.1 53.7 54.6 44.4 57.4
Tumour status
T1, T2 125 68.8 0.59 52.0 0.45 50.4 0.15 51.2 0.55 41.6 0.79 53.6 0.19
T3, T4 48 64.6 58.3 62.5 56.3 43.8 64.6
Nodal status
N0 120 65.0 0.26 53.3 0.86 51.7 0.40 47.5 0.04 42.5 0.90 50.8 0.02
N1, N2 53 73.6 54.7 58.5 64.2 41.5 69.8
Pathological status
Stage I 97 69.1 0.39 51.5 0.54 52.6 0.39 48.5 0.21 40.2 0.78 50.5 0.09
Stage II 17 52.9 47.1 41.2 29.4 41.2 76.5
Stage III 59 69.5 59.3 59.3 66.1 45.8 61.0
Histology
Adenocarcinoma 101 56.4 o0.01 65.3 o0.01 43.6 o0.01 54.5 0.70 45.5 0.22 52.5 0.06
Squamous cell carcinoma 58 87.9 32.8 72.4 51.7 41.4 56.9
Large-cell carcinoma 14 64.3 57.1 50.0 42.9 21.4 85.7
Neoadjuvant MVP chemotherapy
Without neoadjuvant MVP 124 70.9 0.19 52.4 0.69 53.2 0.95 52.4 0.93 43.5 0.68 54.0 0.35
With neoadjuvant MVP 49 59.2 57.1 55.1 53.1 38.8 63.3
Total number of patients 173 67.6 53.8 53.8 52.6 42.2 56.6
NSCLC¼non-small-cell lung cancer; TS¼thymidylate synthase; VEGF¼vascular endothelial growth factor; MVP¼mitomycin/vinblastin/cisplatin.
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sof nodal metastases was significantly higher in E-cadherin-negative
tumours than in E-cadherin-positive tumours (37.8 vs 21.3%,
P¼0.02).
Ki-67 proliferation index in relation to biological markers
in NSCLCs
Concerning TS status, the Ki-67 proliferation index was signifi-
cantly higher in TS-positive tumours than in TS-negative tumours
(48.6729.9 vs 35.6729.8, Po0.01). Regarding VEGF-A status, the
Ki-67 proliferation index was significantly higher in VEGF-A-
positive tumours than in VEGF-A-negative tumours (46.9731.5 vs
37.7728.6, P¼0.04). However, there was no difference in the Ki-
67 proliferation index in relation to VEGF-C or E-cadherin status.
IMD in relation to biological markers in NSCLCs
Concerning VEGF-A status, the IMD was significantly higher in
VEGF-A-positive tumours than in VEGF-A-negative tumours
(118.9751.6 vs 91.1755.8, Po0.01). However, there was no
difference in the IMD in relation to TS, VEGF-C, or E-cadherin status.
Survival of patients with stage I NSCLCs in relation to
biological markers
The 5-year survival rates of 97 patients with stage I NSCLCs in
relation to biological markers are shown in Table 3. With respect
to patients with stage I NSCLCs, there was no significant difference
in the 5-year survival rates between patients with high Ki-67
tumours and those with low Ki-67 tumours (70.0 vs 82.2%,
Figure 1A). In contrast, the 5-year survival rate of patients with
hypervascular tumours was significantly lower than that of
patients with hypovascular tumours (58.3 vs 83.5%, Po0.01,
Figure 1B).
On the other hand, there was no significant difference in the 5-
year survival rates between patients with TS-positive tumours and
those with TS-negative tumours (60.7 vs 81.8%, Figure 1C).
Regarding the TS status and UFT-based chemotherapy, there was
no significant difference in the 5-year survival rates according to
intratumoral TS status and UFT-based chemotherapy among stage
I NSCLCs (Figure 1D). There was also no significant difference in
the 5-year survival rates according to intratumoral TS status and
UFT-based chemotherapy among stage I adenocarcinomas of the
lung (72.2% in UFT-treated patients with TS-negative tumours,
77.2% in UFT-untreated patients with TS-negative tumours, 56.3%
in UFT-treated patients with TS-positive tumours, and 66.7% in
UFT-untreated patients with TS-positive tumours).
In contrast, the 5-year survival rate of patients with VEGF-A-
positive tumours was significantly lower than that of patients with
VEGF-A-negative tumours (58.6 vs 82.2%, P¼0.01, Figure 1E).
The 5-year survival rate of patients with VEGF-C-positive tumours
was also significantly lower than that of patients with VEGF-C-
negative tumours (54.9 vs 80.3%, Po0.01, Figure 1F). Furthermore,
the 5-year survival rate of patients with E-cadherin-negative
tumours was significantly lower than that of patients with E-
cadherin-positive tumours (55.2 vs 85.3%, P¼0.01, Figure 1G).
The multivariate analysis demonstrated that four variables, IMD
(hazard ratio¼3.34, Po0.01), VEGF-A status (hazard ratio¼2.37,
P¼0.03), VEGF-C status (hazard ratio¼2.10, P¼0.03), and E-
cadherin status (hazard ratio¼2.30, P¼0.03), were significant
prognostic factors in patients with stage I NSCLCs (Table 4). The
proportional hazards assumption was met adequately.
Survival of patients with stage II–III NSCLCs in relation to
biological markers
The 5-year survival rates of 76 patients with stage II–III NSCLCs in
relation to biological markers are also shown in Table 3. With
respect to patients with stage II–III (locally advanced) NSCLCs,
the 5-year survival rate of patients with low Ki-67 tumours was
significantly higher than that of patients with high Ki-67 tumours
(43.2 vs 20.0%, P¼0.02, Figure 2A). Especially, the 5-year survival
rate of patients with low Ki-67 tumours was significantly higher
than that of patients with high Ki-67 tumours among stage III (42.8
Table 3 The 5-year survival rate of 173 NSCLC patients in relation to biological markers and pathological stage
Stage I Stage II Stage III Stage II–III Total
Characteristics (%) P-value (%) P-value (%) P-value (%) P-value (%) P-value
Ki-67 index
Low 82.2 0.57 43.8 0.45 42.8 0.04 43.2 0.02 67.0 0.01
High 70.0 33.3 16.7 20.0 44.1
IMD
Hypovascular 83.5 o0.01 50.8 0.30 25.7 0.60 31.1 0.82 62.3 0.02
Hypervascular 58.3 25.0 23.6 24.6 43.1
TS status
Negative 81.8 0.26 45.0 0.23 45.9 o0.01 45.8 o0.01 66.3 o0.01
Positive 60.7 28.6 8.7 12.6 39.2
VEGF-A status
Negative 82.2 0.01 55.6 0.20 35.0 0.75 42.6 0.37 66.5 o0.01
Positive 58.6 0.0 19.3 16.9 38.7
VEGF-C status
Negative 80.3 o0.01 40.0 0.91 27.5 0.75 30.3 0.88 59.2 0.03
Positive 54.9 34.3 21.6 24.3 40.6
E-cadherin status
Positive 85.3 0.01 50.0 0.93 32.6 0.15 35.6 0.28 67.5 o0.01
Negative 55.2 33.8 18.6 22.6 38.9
NSCLC¼non-small-cell lung cancer; IMD¼intratumoral microvessel density; TS¼thymidylate synthase; VEGF¼vascular endothelial growth factor; MVP¼mitomycin/
vinblastin/cisplatin; E-cadherin¼epithelial cadherin.
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svs 16.7%, P¼0.04). However, there was no difference in the 5-year
survival rates between patients with hypovascular tumours and
those with hypervascular tumours (31.1 vs 24.6%, Figure 2B).
Concerning TS status, the 5-year survival rate of patients with
TS-negative tumours was significantly higher than that of patients
with TS-positive tumours among stage II–III (45.8 vs 12.6%,
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Figure 1 Overall survival of patients with stage I NSCLCs in relation to biological markers. (A) Ki-67 index, (B) tumour vascularity, (C) TS status, (D)T S
status and UFT-based chemotherapy, (E) VEGF-A status, (F) VEGF-C status, and (G) E-cadherin status.
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sPo0.01, Figure 2C). Especially, the 5-year survival rate of patients
with TS-negative tumours was significantly higher than that of
patients with TS-positive tumours among stage III (45.9 vs 8.7%,
Po0.01). Regarding TS status and UFT-based chemotherapy,
furthermore, the 5-year survival rates were 53.8% in UFT-treated
patients with TS-negative tumours, 15.0% in UFT-untreated
patients with TS-negative tumours, 15.2% in UFT-treated patients
with TS-positive tumours, and 7.1% in UFT-untreated patients
with TS-positive tumours (Figure 2D). In patients with stage II–III
NSCLCs, the 5-year survival rate of UFT-treated patients with TS-
negative tumours was significantly higher than those of any other
patients (P¼0.04, Po0.01, and Po0.01, respectively).
However, there was no difference in the survival of patients with
stage II–III NSCLCs in relation to intratumoral expressions of
VEGF-A, VEGF-C, or E-cadherin (Figure 2E–G).
The multivariate analysis also demonstrated that the Ki-67
proliferation index (hazard ratio¼2.04, P¼0.02) and TS status
(hazard ratio¼2.43, Po0.01) were significant prognostic factors
in patients with stage II–III NSCLCs (Table 4). The proportional
hazards assumption was met adequately.
DISCUSSION
Recent studies on molecular biology in human cancers have
revealed that many molecules affect various biological behaviours
of malignant tumours. For example, the activation of oncogenes or
the inactivation of tumour suppressor genes, such as K-ras
mutation and p53 mutation, could initially cause malignant
progression (Huang et al, 1998). In addition, reduced expressions
of metastatic suppressor genes, such as E-cadherin (Sulzer et al,
1998; Liu et al, 2001), MRP-1/CD9, and KAI1/CD82 (Adachi et al,
1998), could induce tumour cells with high metastatic potential. In
addition, tumour angiogenesis, affected by various angiogenetic
factors such as the VEGF family (Dvorak et al, 1995), is associated
with not only tumour growth but also tumour metastasis (Folk-
man, 1995).
The clinical use of these biological markers could be classified
into categories as follows: detection of aggressive tumours with a
poor prognosis among early stage tumours (Adachi et al, 1998; Liu
et al, 2001), identification of less aggressive tumours with a
relatively good prognosis among advanced stage tumours, and
selection of effective adjuvant therapies including chemotherapy
(made-to-order medicine) (Rosell et al, 2003; Vokes and Choy,
2003).
Many biological markers have been reported to be correlated
with the survival of NSCLC patients. However, most biological
markers associated with tumour angiogenesis and metastatic
potential are correlated with the prognosis of early-stage NSCLCs
(Adachi et al, 1998; Liu et al, 2001; Masuya et al, 2001). The present
study also demonstrated that the survival of patients with stage I
NSCLCs was significantly lower in patients with hypervascular
tumours than in patients with hypovascular tumours. In addition,
VEGF-C expression, another member of the VEGF family and
reported to induce lymphangiogenesis (Skobe et al, 2001), was also
associated with the prognosis of stage I patients, as reported
previously (Kajita et al, 2001; Arinaga et al, 2003). Furthermore,
previous clinical studies have shown that reduced expressions of
several metastatic suppressor genes, including E-cadherin (Sulzer
et al, 1998; Liu et al, 2001), MRP-1/CD9, and KAI1/CD82 (Adachi
et al, 1998), are also associated with nodal metastases and a poor
prognosis of patients with stage I NSCLCs. Although there were a
few wide CIs for the hazard ratios in Table 4, these results might be
partly because of factors like differing follow-up.
These results indicate that these biological markers associated
with tumour angiogenesis or metastasis are useful for detecting
aggressive tumours with high metastatic potential and a poor
prognosis among early-stage tumours. In contrast, regarding the
methods of surgical resection among stage I NSCLCs, there was no
significant difference in the 5-year survival rates between patients
treated with a lobectomy and patients treated with a segmentect-
omy or a wedge resection (75.3 vs 69.0%, P¼0.18). Therefore,
postoperative adjuvant chemotherapy might be necessary even in
patients with stage I NSCLCs (Arriagada et al, 2004; Kato et al,
2004; Strauss et al, 2004; Winton et al, 2004), when tumours are
hypervascular or have reduced expressions of metastatic suppres-
sor genes.
On the other hand, these biological markers, including tumour
angiogenesis, VEGF-A, VEGF-C, and E-cadherin expression, did
not affect the prognosis of patients with stage II–III NSCLCs in the
present study. Reductions of MRP-1/CD9 and KAI1/CD82 were
also reported to not be correlated with the survival of locally
advanced stage patients (Adachi et al, 1998). Thus, tumour
angiogenesis and tumour metastatic suppressor genes are not
clinical indicators for patients with locally advanced NSCLCs.
These results urged us to perform the present study.
We evaluated the tumour proliferation rate using the Ki-67
proliferation index (Scagliotti et al, 1993). Ki-67 antibody
recognises the nuclear antigen expressed during G1, S, G2, and
M phases of the cell cycle and not during the resting (G0) phase.
The present study has demonstrated that the Ki-67 proliferation
index is one of the significant prognostic factors in patients with
stage II–III NSCLCs. In contrast, the Ki-67 proliferation index was
not associated with the prognosis of stage I patients.
Regarding TS, its expression is regulated by a polymorphic
tandem repeat sequence in the 50-terminal regulatory region of TS
gene (Horie et al, 1995), and it is also regulated by several
oncogenes and tumour suppressor genes, including E2F1, retino-
blastoma, and p16/INK4 (DeGregori et al, 1995; Omura et al, 2000;
Angus et al, 2002). Thymidylate synthase plays a central role in the
biosynthesis of thymidylate, an essential precursor for DNA
synthesis. Recent studies have revealed that TS exhibits onco-
gene-like activity. Its expression is associated with tumour cell
proliferation (Navalgund et al, 1980), as demonstrated in the
Table 4 Multivariate regression analyses in predicting survival of NSCLC patients
Stage I Stage II, Stage III
Biological markers Hazard ratio 95% CI P-value Hazard ratio 95% CI P-value
Ki-67 index 1.75 0.73–4.21 0.20 2.04 1.09–3.80 0.02
IMD 3.34 1.30–7.86 o0.01 1.38 0.75–2.54 0.28
TS status 1.31 0.57–2.98 0.51 2.43 1.34–4.42 o0.01
VEGF-A status 2.37 1.07–5.24 0.03 1.27 0.69–2.35 0.43
VEGF-C status 2.10 1.01–4.37 0.03 0.94 0.54–1.64 0.83
E-cadherin status 2.30 1.03–5.16 0.03 1.50 0.85–2.63 0.15
NSCLC¼non-small-cell lung cancer; CI¼confidence interval; IMD¼intratumoral microvessel density; TS¼thymidylate synthase; VEGF¼vascular endothelial growth factor;
MVP¼mitomycin/vinblastin/cisplatin; E-cadherin¼epithelial cadherin.
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spresent study. Thymidylate synthase protein also downregulates
p53 expression through TS protein–p53 mRNA interaction (Chu
et al, 1999). In addition, TS can induce a transformed phenotype in
mammalian cells (Rahman et al, 2004). The present study has
demonstrated that the intratumoral TS expression is one of
significant prognostic factors in patients with stage II–III NSCLCs.
Furthermore, the intratumoral TS activity has been reported to
be related to 5-FU sensitivity (Beck et al, 1994). Several clinical
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Figure 2 Overall survival of patients with stage II–III NSCLCs in relation to biological markers. (A) Ki-67 index, (B) tumour vascularity, (C) TS status, (D)
TS status and UFT-based chemotherapy, (E) VEGF-A status, (F) VEGF-C status, and (G) E-cadherin status.
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sstudies have demonstrated that long-term oral UFT is effective
postoperative adjuvant chemotherapy for NSCLC, especially in
terms of patient quality of life (Wada et al, 1996; Kato et al, 2004).
Many clinical studies on human cancers, including NSCLCs and
gastrointestinal tumours, have shown that high TS expression is
associated with 5-FU resistance and a poor outcome (Johnston
et al, 1995; Yeh et al, 1998; Huang et al, 2000). In the present study,
the 5-year survival rate of UFT-treated patients with TS-negative
tumours was 53.8%, even in stage II–III, which was significantly
higher than those of any other group (7.1–15.2%). A recent study
has demonstrated that adjuvant chemotherapy with UFT improves
the survival among patients with stage I adenocarcinoma of the
lung (Kato et al, 2004). In the present study, however, there was no
difference in the 5-year survival rates according to the intratumor-
al TS status and UFT-based chemotherapy among stage I NSCLCs
or among stage I adenocarcinomas. These results might be partly
due to the small number of patients studied.
These results suggest that the tumour proliferation rate and TS
status are useful markers for identifying less aggressive tumours in
locally advanced NSCLCs, and that TS expression is also a useful
marker to evaluate responsiveness of UFT-based chemotherapy for
these tumours. To our knowledge, there were few clinical reports
to identify biological markers useful for the treatment of patients
with locally advanced NSCLCs.
These findings indicate that evaluations of these markers,
including the tumour proliferation index and target molecules for
chemotherapy, would improve the clinical outcome of patients
with locally advanced NSCLCs. Other than TS for UFT, epithelial
growth factor receptor for Gefitinib (Mendelsohn and Baselga,
2003) and topoisomerase II for etoposide (Dingemans et al, 1999)
might be useful target markers for chemotherapy in advanced
NSCLC patients. In addition, such targeted therapies may lead to
the development of made-to-order medicine, a new therapeutic
strategy for cancer (Rosell et al, 2003; Vokes and Choy, 2003).
Regarding target therapies, the present study was a retrospective
clinical study with some limitations in its analysis. A further
prospective randomised clinical study based on an evaluation of
such biological markers, as the NCIC BR.19 study on adjuvant
Gefitinib therapy (National Cancer Institute Central IRB protocol,
2002), should be performed.
ACKNOWLEDGEMENTS
We thank Dr Masakazu Fukushima (Taiho Pharmaceutical Co.,
Tokyo, Japan) for his kind gift of a rabbit polyclonal antibody
for TS.
REFERENCES
Adachi M, Taki T, Konishi T, Huang C, Higashiyama M, Miyake M (1998)
Novel staging protocol for non-small-cell lung cancers according to
MRP-1/CD9 and KAI1/CD82 gene expression. J Clin Oncol 16: 1397–1406
Angus SP, Wheeler LJ, Ranmal SA, Zhang X, Markey MP, Mathews CK,
Knudsen ES (2002) Retinoblastoma tumour suppressor targets dNTP
metabolism to regulate DNA replication. J Biol Chem 277: 44376–44384
Arinaga M, Noguchi T, Takeno S, Chujo M, Miura T, Uchida Y (2003)
Clinical significance of vascular endothelial growth factor C and vascular
endothelial growth factor receptor 3 in patients with nonsmall cell lung
carcinoma. Cancer 97: 457–464
Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP,
Vansteenkiste J, International adjuvant lung cancer trial collaborative
group (2004) Cisplatin-based adjuvant chemotherapy in patients with
completely resected non-small-cell lung cancer. N Engl J Med 350:
351–360
Beck A, Etienne MC, Cheradame S, Fischel JL, Formento P, Renee N,
Milano G (1994) A role for dihydropyrimidine dehydrogenase and
thymidylate synthase in tumour sensitivity to fluorouracil. Eur J Cancer
30A: 1517–1522
Cersosimo RJ (2002) Lung cancer: a review. Am J Health-Syst Ph 59:
611–642
Chu E, Copur SM, Ju J, Chen T, Khleif S, Voeller DM, Mizunuma N, Patel
M, Maley GF, Maley F, Allegra CJ (1999) Thymidylate synthase protein
and p53 mRNA form an in vivo ribonucleoprotein complex. Mol Cell Biol
19: 1582–1594
Cox DR (1972) Regression models and life-tables. J R Stat Soc Ser B 34:
187–202
DeGregori J, Kowalik T, Nevins JR (1995) Cellular targets for activation by
the E2F1 transcriptional factor include DNA synthesis- and G1/S-
regulatory genes. Mol Cell Biol 15: 4215–4224
Dingemans AC, Witlox MA, Stallaert RA, van der Valk P, Postmus PE,
Giaccone G (1999) Expression of DNA topoisomerase IIa and
topoisomerase IIb genes predicts survival and response to chemotherapy
in patients with small cell lung cancer. Clin Cancer Res 5: 2048–2058
Dvorak HF, Brown LF, Detmar M, Dvorak AM (1995) Vascular perme-
ability factor/vascular endothelial growth factor, microvascular hyper-
permeability, and angiogenesis. Am J Pathol 146: 1029–1039
Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other
disease. Nat Med 1: 27–31
Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H (1984)
Cell cycle analysis of a cell proliferation-associated human nuclear
antigen defined by the monoclonal antibody Ki-67. J Immunol 133:
1710–1715
Grambsch PM, Therneau TM (1994) Proportional hazards tests and
diagnostics based on weighted residuals. Biometrika 81: 515–526
Horie N, Aiba H, Oguro K, Hojo H, Takeishi K (1995) Functional analysis
and DNA polymorphism of the tandemly repeated sequences in the 50-
terminal regulatory region of the human gene for thymidylate synthase.
Cell Struct Funct 20: 191–197
Huang C, Taki T, Adachi M, Konishi T, Higashiyama M, Kinoshita M,
Hadama T, Miyake M (1998) Mutations of p53 and K-ras genes as
prognostic factors for non-small cell lung cancer. Int J Oncol 12: 553–563
Huang C, Yokomise H, Kobayashi S, Fukushima M, Hitomi S, Wada H
(2000) Intratumoral expression of thymidylate synthase and dihydro-
pyrimidine dehydrogenase in non-small cell lung cancer patients treated
with 5-FU-based chemotherapy. Int J Oncol 17: 47–54
Imoto H, Osaki T, Taga S, Ohgami A, Ichiyoshi Y, Yasumoto K (1998)
Vascular endothelial growth factor expression in non-small-cell lung
cancer: prognostic significance in squamous cell carcinoma. J Thorac
Cardiovasc Surg 115: 1007–1014
Johnston PG, Lenz H, Leichman CG, Danenberg KD, Allegra CJ, Danenberg
PV, Leichman L (1995) Thymidylate synthase gene and protein
expression correlate and are associated with response to 5-fluorouracil
in human colorectal and gastric tumors. Cancer Res 55: 1407–1412
Kajita T, Ohta Y, Kimura K, Tamura M, Tanaka Y, Tsunezuka Y, Oda M,
Sasaki T, Watanabe G (2001) The expression of vascular endothelial
growth factor C and its receptors in non-small cell lung cancer. Br J
Cancer 85: 255–260
Kato H, Ichinose Y, Ohta M, Hata E, Tsubota N, Tada H, Watanabe Y,
Wada H, Tsuboi M, Hamajima N, Ohta M, Japan Lung Cancer Research
Group on Postsurgical Adjuvant Chemotherapy (2004) A randomized
trial of adjuvant chemotherapy with uracil–tegafur for adenocarcinoma
of the lung. N Engl J Med 350: 1713–1721
Liu D, Huang C, Kameyama K, Hayashi E, Yamauchi A, Kobayashi S,
Yokomise H (2001) E-cadherin expression associated with differentiation
and prognosis in patients with non-small cell lung cancer. Ann Thorac
Surg 71: 949–955
Machtay M, Lee JH, Stevenson JP, Shrager JB, Algazy KM, Treat J, Kaiser LR
(2004) Two commonly used neoadjuvant chemotherapy regimens for
locally advanced stage III non-small cell lung carcinoma: long-term
results and associations with pathologic response. J Thorac Cardiovasc
Surg 127: 108–113
Martin J, Ginsberg RJ, Venkatraman ES, Bains MS, Downey RJ, Korst RJ,
Kris MG, Rusch VW (2002) Long-term results of combined-modality
therapy in resectable non-small-cell lung cancer. J Clin Oncol 20:
1989–1995
Biological markers in lung cancer
C Huang et al
1238
British Journal of Cancer (2005) 92(7), 1231–1239 & 2005 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sMasuya D, Huang C, Liu D, Kameyama K, Hayashi E, Yamauchi A,
Kobayashi S, Haba R, Yokomise H (2001) The intratumoral expression
of vascular endothelial growth factor and interleukin-8 associated
with angiogenesis in nonsmall cell lung carcinoma patients. Cancer 92:
2628–2638
Matsuyama K, Chiba Y, Sasaki M, Tanaka H, Muraoka R, Tanigawa N
(1998) Tumor angiogenesis as a prognostic marker in operable non-
small cell lung cancer. Ann Thorac Surg 65: 1405–1409
Mbalaviele G, Dunstan CR, Sasaki A, Williams PJ, Mundy GR, Yoneda T
(1996) E-cadherin expression in human breast cancer cells suppresses
the development of osteolytic bone metastases in an experimental
metastasis model. Cancer Res 56: 4063–4070
McCarty Jr KS, Szabo E, Flowers JL, Cox EB, Leight GS, Miller L, Konrath J,
Soper JT, Budwit DA, Creasman WT, Seigler HF, McCarty Sr KS (1986)
Use of a monoclonal anti-estrogen receptor antibody in the immuno-
histochemical evaluation of human tumors. Cancer Res 46: 4244s–4248s
Mendelsohn J, Baselga J (2003) Status of epidermal growth factor receptor
antagonists in the biology and treatment of cancer. J Clin Oncol 21:
2787–2799
Mountain CF (1997) Revisions in the international system for staging lung
cancer. Chest 111: 1710–1717
Nakashima T, Huang C, Liu D, Kameyama K, Masuya D, Ueno M, Haba R,
Yokomise H (2004) Expression of vascular endothelial growth factor-A
and vascular endothelial growth factor-C as prognostic factors for non-
small cell lung cancer. Med Sci Monit 10: 157–165
National Cancer Institute Central IRB protocol (2002) NCIC BR.19. A phase
III prospective randomized, double-blind, placebo-controlled trial of the
epidermal growth factor receptor antagonist, ZD1839 (Iressa) in
completely resected primary stage IB, II and IIIA non-small cell lung
cancer. http://www.ncicirb.org/CIRB_Protocols.asp
Navalgund LG, Rossana C, Muench AJ, Johnson LF (1980) Cell cycle
regulation of thymidylate synthetase gene expression in cultured mouse
fibroblasts. J Biol Chem 255: 7386–7390
Omura K, Uno Y, Kawakami K, Kanehira E, Tawaraya K, Tsukayama M,
Hiranuma C, Watanabe Y (2000) Expression of thymidylate synthase in
human gastric and colorectal adenocarcinomas is upregulated by p16/
INK4. Hepatogastroenterology 47: 742–745
Rahman L, Voeller D, Rahman M, Lipkowitz S, Allegra C, Barrett JC, Kaye
FJ, Zajac-Kaye M (2004) Thymidylate synthase as an oncogene: a novel
role for an essential DNA synthesis enzyme. Cancer Cell 5: 341–351
Rosell R, Taron M, Alberola V, Massuti B, Felip E (2003) Genetic testing for
chemotherapy in non-small cell lung cancer. Lung Cancer 41: S97–S102
Scagliotti GV, Micela M, Gubetta L, Leonardo E, Cappia S, Borasio P, Pozzi
E (1993) Prognostic significance of Ki67 labelling in resected non small
cell lung cancer. Eur J Cancer 29A: 363–365
Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes L, Velasco P, Riccardi
L, Alitalo K, Claffey K, Detmar M (2001) Induction of tumor
lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat
Med 7: 192–198
Strauss GM, Herndon J, Maddaus MA, Johnstone DW, Johnson EA, Watson
DM, Sugarbaker DJ, Schilsky RL, Green MR (2004) Randomized clinical
trial of adjuvant chemotherapy with paclitaxel and carboplatin following
resection in stage IB non-small cell lung cancer (NSCLC): report of
cancer and leukemia group B (CALGB) protocol 9633. Proc Am Soc Clin
Oncol 22: 621 (abstract 7019)
Sulzer MA, Leers MP, van Noord JA, Bollen EC, Theunissen PH (1998)
Reduced E-cadherin expression is associated with increased lymph node
metastasis and unfavorable prognosis in non-small cell lung cancer. Am J
Respir Crit Care Med 157: 1319–1323
Vokes EE, Choy H (2003) Targeted therapies for stage III non-small cell
lung cancer: integration in the combined modality setting. Lung Cancer
41: S115–S121
Wada H, Hitomi S, Teramatsu T (1996) Adjuvant chemotherapy
after complete resection in non-small-cell lung cancer. J Clin Oncol 14:
1048–1054
Winton TL, Livingston R, Johnson D, Rigas J, Cormier Y, Butts C, Ding K,
Seymour L, Magoski N, Shepherd F (2004) A prospective randomised
trial of adjuvant vinorelbine (VIN) and cisplatin (CIS) in completely
resected stage IB and II non small cell lung cancer (NSCLC) Intergroup
JBR. 10. Proc Am Soc Clin Oncol 22: 621 (abstract 7018)
Yeh K, Shun C, Chen C, Lin J, Lee W, Lee P, Chen Y, Cheng A (1998) High
expression of thymidylate synthase is associated with the drug resistance
of gastric carcinoma to high dose 5-fluorouracil-based systemic
chemotherapy. Cancer 82: 1626–1631
Biological markers in lung cancer
C Huang et al
1239
British Journal of Cancer (2005) 92(7), 1231–1239 & 2005 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
s